Investment Opportunity
A Delivery Platform, Validated by Our Own Oncology Programs
Xelcis Bio™ is advancing XELCIS XB, a nanoparticle platform engineered to deliver therapeutics to the cytosol, the intracellular compartment where most oncology payloads must act and where the majority are lost to endosomal entrapment. We are validating the platform through our own programs, led by targeted doxorubicin, TDOX, and making the same delivery engine available to partners whose assets are constrained by intracellular access.
SCROLL
Investment Opportunity
Addressing a High-Value Bottleneck
Failure to achieve cytosolic delivery is a major source of attrition across multiple oncology modalities. By enabling functional intracellular activity, XELCIS XB is positioned to unlock value across existing portfolios and emerging therapeutic classes.
Why Delivery Is the Opportunity
Many high-value oncology programs, including RNA therapeutics, targeted protein degraders, and intracellularly acting biologics, fail not because the biology is flawed but because the payload never reaches its intracellular site of action. Endosomal entrapment, not target validation, is frequently the limiting step. A platform that improves cytosolic delivery across modalities therefore has leverage across the entire portfolio, not a single asset.
Market Opportunity
Platform Leverage Across Large Markets
XELCIS XB addresses delivery constraints across multiple therapeutic modalities, each representing a significant commercial opportunity.
$10B+
Targeted Chemotherapy
Our lead program: XELCIS XB conjugated to doxorubicin via Z-Link, designed to overcome multidrug resistance while sparing the heart. It also anchors two dual-payload combination programs.
$3B+
RNAi / Nucleic Acids
RNA therapeutics depend on intracellular delivery, and endosomal escape remains the central barrier to functional activity. XELCIS XB delivers siRNA payloads to the cytosol, the basis of our siPD-L1-Dox and siBIRC5-Dox combination programs.
$3B+
Biologics and Nanobodies
Intracellularly acting biologics and nanobodies face the same endosomal barrier. XELCIS XB is designed to deliver these larger payloads to the cytosol, supported by a completed protein-delivery proof of concept.
$12B+
Protein Degraders
PROTACs and molecular glues require cytosolic delivery to drive functional degradation. XELCIS XB extends to this class as a longer-horizon platform capability and partnering opportunity.
Business Model
Two Engines: Proprietary Programs and Platform Partnerships
Xelcis pursues a capital-efficient strategy with two reinforcing engines. We intend to advance proprietary therapeutics, led by TDOX, that capture value directly, and to license the same platform to partners whose assets are limited by intracellular delivery. Internal programs de-risk and validate the platform; partnerships extend it across modalities we do not develop ourselves.
Proprietary Programs
Advance owned therapeutics, led by TDOX and two dual-payload combination programs, that generate standalone value and validate XELCIS XB in defined disease settings.
Target-Specific Partnerships
Collaborate around individual assets within a partner's portfolio, enabling rapid technical evaluation and efficient go/no-go decisions.
Platform Licensing
License XELCIS XB delivery rights for defined targets or programs in exchange for upfront fees, R&D support, milestones, and royalties.
Use of Funds
Use of Proceeds: Reaching IND-Enabling Readiness
This round advances TDOX into in vivo studies, with the two dual-payload combination programs progressing on the same platform. The resulting data package is structured to de-risk the subsequent priced round, which will carry TDOX toward an IND.
Lead Program In Vivo Studies
Delivery, tolerability, biodistribution, and efficacy data for TDOX, XB-siBIRC5-DOX, and XB-siPD-L1-DOX in tumor models, including target engagement and knockdown readouts for the combination programs.
Manufacturing Readiness
Process development and analytical characterization of the XELCIS XB conjugates, so material is ready for IND-enabling work and partner evaluation.
Path to Next Round
A diligence-ready data and IP package built to support the next financing and early partnership discussions in parallel.
Connect
Join Us in Building the Next Generation of Oncology Delivery
Xelcis Bio is currently securing financing to further develop its proprietary oncology initiatives. The company is also actively engaging with partners whose assets are limited by intracellular delivery challenges. If these areas align with your interests, we welcome the opportunity to discuss.